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Nobody ever figures out what life is all about, and it doesn’t matter. Explore the world.
Nearly everything is really interesting if you go into it deeply enough.
Richard P. Feynman
Abstract
The aim of this study, carried out at the Center for Proton Therapy of the Paul Scherrer
Institute (Villigen, Switzerland), involves the verification of the possibility of 4D treat-
ments on patients requesting a patch field. This technique is used when the dimensions
of the area to be irradiated are greater than 12 cm for the T direction and 20 cm for the
U direction. We also went to research the setup that provides a better dose homogeneity,
in order to mitigate the tumor’s motion during the treatment.
Three clinical cases were studied with the motions obtained from the respective
4DCT. Moreover, one of these was analyzed again simulating a motion extrapolated
from a 4D-MRI. All 4 cases were analyzed in 9 combinations, 3 possible rescan scenarios
(1, 4 and 8 rescan) and 3 different overlapping setups between the two patches (0, 1 and
2 cm of overlap). The values obtained were compared to the 3D plan. The dose homo-
geneity measures (D5-D95 and V95) showed that in the case of a slight motion (under 2
mm) there was no need to intervene with motion mitigation. For the motions classified
of medium intensity (2-10 mm), it was found the need to introduce motion mitigation.
In none of the previous cases, a systematic benefit emerged with a certain pattern of
patch overlap. It was not possible to fully evaluate the last case, having a large motion
(about 20 mm), as it needed an IMPT plan (technique not yet developed for the 4D),
but still indications, regarding the benefit of the use of 8 rescan and greater possible
overlap, emerged. The experimental measurements obtained at Gantry 2 with the use
of a 2D detector (Octavius 1500 XDR), a gating system and a Quasar motion platform,
confirmed that there are no problems with the actual dose release. The homogeneity of
the dose is also found when there are extreme conditions, such as 2 cm overlap, 8 rescan
and 4 patches (for a 4 cm zone receiving 32 rescan) and a strong simulated motion.

Sommario
Lo scopo di questo studio, svolto presso il Center for Proton Therapy del Paul Scherrer
Institute (Villigen, Svizzera), prevede la verifica della possibilità di effettuare trattamenti
4D su pazienti richiedenti un patch field. Tale tecnica viene utilizzata quando le dimen-
sioni della zona da irraggiare sono maggiori di 12 cm per la direzione T e di 20 cm per la
direzione U. Si è, inoltre, andati a ricercare il setup che fornisse una miglior omogeneità
di dose. Sono stati studiati tre casi clinici con i moti ottenuti dalle rispettive 4DCT.
Inoltre, uno di questi è stato analizzato nuovamente simulando un moto estrapolato da
una 4D-MRI. Tutti e 4 i casi sono stati analizzati in 9 combinazioni, 3 possibili scenari
di rescan (1, 4 e 8 rescan) e 3 diversi setup di sovrapposizione dei due patch (0, 1 e 2
cm di sovrapposizione). I valori ottenuti sono stati messi a confronto con il piano 3D. Le
misure di omogeneità della dose (D5-D95 e V95) hanno mostrato come nel caso avente
un moto di lieve entità (circa 2 mm) non vi fosse necessità di intervenire con mitigazione
del moto. Per i moti classificati di media intensità (2-10 mm), si è riscontrata la necessità
di introdurre una mitigazione del moto. In nessuno dei casi precedenti è emerso un be-
neficio sistematico con una determinata configurazione della sovrapposizione del patch.
Non è stato possibile valutare a pieno l’ultimo caso, avente un moto di grande entità
(circa 20 mm), in quanto necessitava di un piano IMPT (tecnica ancora non sviluppata
per il 4D), ma ha comunque dato indicazioni riguardanti il beneficio dell’utilizzo di 8
rescan e una maggiore sovrapposizione possibile. Le misurazioni sperimentali ottenute
presso Gantry 2 con l’utilizzo di un rivelatore 2D (Octavius 1500 XDR), un sistema di
gating e una piattaforma mobile Quasar, hanno confermato che non vi sono problemi per
quanto riguarda l’effettivo rilascio della dose. L’omogeneità della dose si è riscontrata
anche quando ci sono delle condizioni estreme, come 2 cm overlap, 8 rescan e 4 patch
(per una zona di 4 cm ricevente 32 rescan) e un forte moto simulato.
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Part I
Background
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Introduction
Hadron therapy is the radiotherapy for cancer treatments that uses heavy charged par-
ticle, hadrons, if only protons are used it is called proton therapy. Thanks to the control
for size, shape, and depth, due to no exit dose, proton therapy is emerging as therapy
of choice over conventional radiotherapy. Research is starting to study treatment in-
volving organs like lungs and liver. These organs at risk presents complications, such as
the presence of many critical structures that lie close to the target, and the presence of
motion. Many techniques have been developed to mitigate the intrafraction motion, but
the level of 3D treatments has not been reached yet. In the course of this thesis, that
has been carried out for a duration of 6 months in the Center for Proton Therapy at
Paul Scherrer Institute (Villigen, Switzerland), we have studied the feasibility to deliver
4D treatments that required patches.
In the delivery of proton therapy, it is sometimes necessary to split a field into two or
more parts, since the dimensions of the target volume exceed the deliverable size of the
gantry. In 4D cases this can be particularly problematic since the patching zone moves
during the irradiation; the introduction of motion mitigation is therefore necessary. In
order to verify the feasibility of 4D treatments with patches, we developed a new tool to
permit the dose visualization of a single patch, a new version of the TPS for the 4DDC,
a new procedure to deliver experimental verifications and a new version of the MATLAB
script to evaluate the mid-ventilation phase in case of metastasis.
In chapter 1 of the thesis it is exposed a short introduction to proton therapy, with
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particular attention to the physics behind it and the biological effects induced by the
proton beam. A quick view on history and a brief introduction to cyclotron are also
explained.
In chapter 2 the attention is initially on the PSI facilities, after that it goes more into
the specifics of our problematics like the planning of the dose and the theory behind 4D
treatments. The last part of the chapter will be fundamental to understand why and
how the experimental work was done.
In chapter 3 it is explained what patch fields are and how the 4D dose calculation
works, as those were the specific parts of the 4D workflow that were changed in the
course of the thesis work. After a brief introduction to the clinical cases used, results are
exposed with a discussion about how they were generated and what indications emerge
from them.
In chapter 4 the experimental verifications are explained, showing the experimental
setup used and the results. A discussion of the results follows at the end of the chapter.
Possible outlooks for future investigations are proposed in the last paragraph called
conclusions.
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Chapter 1
Proton therapy
1.1 History
The history of external radiotherapy begins in 1895, thanks to Emil Grubbe, who used X-
rays to treat a woman with a carcinome of the breast, just one year after their discovery.
Since radiation therapy was becoming more and more important in oncology, many
improvements were done in the following decades. Since the beginning of the twentieth
century, the main issue was the reduction of the dose to healthy tissues while maintaining
the prescribed dose to the target. Fractionated radiation therapy was an initial step, and
after that in the thirties it began the study about the dose deposition of different types
of particles. In 1946 for the first time the use of protons was suggested by R. R. Wilson
[1], but it was only in the next decade that first treatment on patient started and just
in nuclear physics research facilities. A disadvantage of this technique was in the low
energy achievable by the accelerators; in fact, as they were not designed specifically
for treatments, they didn’t permit to treat deeply seated tumors. At the beginning
of the sixties, the facilities started to treat a bigger set of tumor classes, especially
the brain tumor, but it was just in 1970, with the introduction on the clinic use of
Computed Tomography (CT), that the dose calculation started to be more accurate
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and the proton therapy started to be used in a hospital. The world’s first hospital-
based proton therapy center was the Massachusetts General Hospital (MGH), opened
in the late Seventies, that made the first treatment in 1970, followed by Paul Scherrer
Institute (PSI) in 1984. Subsequently, a low energy cyclotron center for ocular tumors
at the Clatterbridge Center for Oncology in the UK, opened in 1989, followed by Loma
Linda University Medical Center in California in 1990. In Italy there are currently 3
centers: CATANA (in Catania, hadron-therapy only for ocular tumors), CNAO (Centro
Nazionale di Adroterapia Oncologica, in Pavia) and the IBA center in Trento. Another
center is actually under construction in Rome and should start the firsts treatments in
2020. The traditional indications for proton therapy have been treatments of head and
neck, brain, and prostate cancer, but growing results from its application for other cancer
types are proving to be positive. In 2013, 105743 patients [2] were treated with proton
therapy, a number that is anticipated to grow larger and faster as new proton therapy
centers continue to open within the next several years.
1.2 Physics of Proton therapy
A proton is a subatomic particle, with a positive electric charge and it is a basic compo-
nent of the nucleus of atoms. Protons have three main types of interactions with matter:
scattering, stopping and nuclear interactions [3]
Scattering Scattering is explained by a theory that concerns the deflection caused by
electromagnetic interaction between atomic nuclei and protons. The effect of a single
nucleus interaction is countless, but as the number of nuclei is extremely high, it is
possible to see an effect and therefore the outcome will have a statistical nature. Since
the scattering is due to the electromagnetic force it is also known with the name ”multiple
Coulomb scattering”. The effect is a lateral spread out of the proton beam, and the
statistical outcome, due to the central limit theorem, is similar to a Gaussian. It is not
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possible to assume the outcome as a normal Gaussian, because large single scatters in
the target are not rare enough. Typical values of the related half-width are around a few
degrees, with 16 in the worst scenario [3].
Stopping Stopping is explained by a theory that concerns the interaction between
atomic electrons and protons and it induces a slowdown of the beam. This is the key
feature of the advantage of using protons: they do not have an exit dose because beyond
the stopping point the dose can be considered negligible.
A new quantity, called range, defined as the mean path length of protons with initial
energy E0 in the matter, is formulated in the continuous slowing down approximation
R = −
∫ 0
E0
dE
dE/dx
(1.1)
.
Stochastic nature of the energy loss causes the range straggling, in a mono-energetic
proton-beam, all protons will stop more or less at the same depth, with a slight spread
in the stopping point. The effect will be more visible if the original beam has a spread
in energy. The straggling is around 1.2% of range and it slightly changes between light
and heavy materials [4].
Concerning the theory of stopping a characteristic rate of energy lost by protons
emerges, described by the so-called stopping power. Due to the fact that protons stay
longer in the vicinity of electrons when they are slower, they will also interact more and
lose more energy [3].
Nuclear interactions Nuclear interactions are not only of one type, and they are not
explained by a single theory. It is also really difficult to model them in a proper way,
but luckily their biological effect is really small and, with some approximation we still
have a good comprehension of the environment, such that we can design radiotherapy
treatments safely. Nonelastic interactions result to be the most interesting ones, because
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they produce secondary particles: charged (protons and α) and not charged (neutrons
and γ-rays). The effect of those particles will be a larger spread of the dose deposition,
due to their bigger emission angles.
1.3 Bethe-Bloch formula
The quantity called stopping power, or simply dE/dx, was initially calcutaled by Bohr,
with a classic approach, giving this relation:
−dE
dx
=
4πz2e4
mev2
Ne ln
γ2mev
3
ze2v̄
(1.2)
while the quantum mechanic results were formulated by Bethe and Bloch. The Bethe-
Bloch formula, here presented in the full version with density correction δ and shell
correction C, is:
dE
dx
= 2πNar
2
emec
2ρ
Z
A
z2
β2
[
ln
(
2meγ
2v2Wmax
I2
)
− 2β2 − δ − 2C
Z
]
(1.3)
where re is the classic electron radius, me is the electron mass, Na is the Avogadro
number, I is the average potential of eccitation, Z is the atomic number of the material
hit, A is the number of mass of the material hit, is the density of the material, z is the
charge of the incident particle in e unit, β = v/c of the incident particle, γ = 1/
√
1− β2,
Wmax is the maximum energy that can be transferred in a single collision.
The two corrections are important respectively at high and low energies. The δ
correction comes from the polarization of the atoms along the path of the carged particles,
induced by their electric field. This effect becomes important when the energy of the
particle increase and it also depends on the density of the material hit.
Shell correction C takes into account an effect that comes into play when the speed
of the particles is close, or even smaller, than the atomic electrons one. In this case, it
is no more possible to assume the electron with no motion respect to the beam, so that
we have to add this correction.
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Figure 1.1: Stopping power of different ions in function of different energies. [?]
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In Figure 1.1 the stopping power of different ions is presented in function of the energy.
It is easy to see that, for non-relativistic energies, dE/dx is principally dominated by
the 1/β2 factor that decreases when the energy increases. This trend has an important
variation when v ' 0.96c, the stopping power reaches a minimum. After this spot the
1/β factor keep constant and the dE/dx increase again following the log of the formula
1.3.
Analyzing Figure 1.1 it is clear that a heavy charged particle will have a bigger
stopping power when its kinetic energy is smaller and that it will slow down while it
penetrates more trough the matter. The main consequence is that the particle releases
more energy per unit of length at the end of the path than at the beginning, as can be
seen in Figure 1.2 that shows a Bragg curve for an alpha particle in air.
Figure 1.2: Typical Bragg curve that shows the variation of the stopping power in
function of the path in matter.
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Thanks to this way of interacting we can assume that charged particles, or in this
case specifically protons, give the great advantage to be easily controllable in all three
dimensions, while with photons it was possible just with two of them and moreover it is
not easy.
Currently, for analytical dose planning algorithm in particle therapy, a new quantity,
Relative Proton Stopping Power (RPSP), is considered, that is the stopping power ratio
Ŝ of a medium relative to water. It can be approximated without shell and density
correction by the following formula [5]:
Ŝ ≡ S
Sw
≈ ρe
ρe,w
·
ln
(
2mec2β2
I(1−β2) − β
2
)
ln
(
2mec2β2
Iw(1−β2) − β
2
) = ρ̂e · f(β, I, Iw) . (1.4)
The RPSP, for energies above 15 MeV/nucleon, can be considered largely energy inde-
pendent, as its dependence is below 0.4% [6], while below this limit it is ignored by most
analytical dose planning systems. For this reason, considering a mean particle energy
equal to 200 MeV/nucleon and setting the mean excitation value of water at 75 eV,
equation 1.4 can be approximated to:
Ŝ ≈ ρ̂e ·
12.77− ln I
8.45
. (1.5)
1.4 Biological effects of ionizing radiation
Radiation is classified into ionizing and not ionizing based on its ability to ionize the
medium. Ionizing radiation can be divided into two main categories:
• Directly ionizing: radiation produces ions directly (protons, β±);
• Indirectly ionizing: radiation produces ions in an indirect way (X-rays, γ, neu-
trons).
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1.4.1 DNA damage
Biological damage caused by radiations results from the ionization of atoms forming
molecular structures of cells in living organisms. An ionized atom will tend to produce
new chemical bonds within the molecule to which it belongs. The vital functions of the
cell can be compromised if the damaged molecule is critical within the cell.
Deoxyribonucleic acid, DNA, is a nucleic acid that contains the genetic information
necessary to the biosynthesis of RNA and protein molecules essential, for the develop-
ment and proper functioning of most living organisms. DNA is formed by four different
nitrogenous bases: two purine bases (Adenine and Guanine) and two pyrimidine base
(Thymine and Cytosine) which, assembled in groups of three (triplets), are organized
into chains of nucleotides forming the various genes located on chromosomes. Each gene
provides for the coding of a particular protein. Each triplet determines a well-defined
amino acid into the protein. Any errors occurring in response to radiation may lead to
position changes of the triplets in DNA molecules, resulting in coding errors for protein
building. Such changes can lead to diseases of genetic origin.
The radio-induced structural alteration of the nucleic acid has a lethal effect on
the cell when the cell loses its ability to divide. This occurs because of an irreparable
impairment of hereditary information encoded in the nucleotide sequence of the DNA.
It can occur through three main mechanisms:
• breaking of the main chain;
• intramolecular bridges formation (covalent bonds, cross-link) that block the dupli-
cation process, preventing the separation of the two strands of the nucleic acid;
• structural modification of purine and pyrimidine bases. This can lead to a gene
mutation of greater or lesser gravity in function of the character coded by the gene
involved.
15
Figure 1.3: Principal DNA damage types induced by ionizing radiation. [43]
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The breaking of a single chain occurs when damage to one of the two chains leaves
the complementary strand intact. The repair mechanism of this kind of damage is quite
simple: the section of the chain containing the breakage is removed and then rebuilt
employing the complementary chain as a reference and finally reconnected by an enzyme
called ligase. The number of single strand break has been shown to be linearly related to
the dose of radiation within a very wide range. The average energy required to produce a
single break is comprised between 10 and 20 eV in the case of weakly ionizing radiation.
The breaking of the double chain occurs when two breakages on individual adjacent
chains cause the detachment of part of the DNA. A double breakage can derive either
from ionizing events due to the same radiation, affecting two chains simultaneously or
from the combination of two events due to different single breaking events which, inci-
dentally, affect two nearby points of two chains of the same macromolecule. The former
happens especially with highly ionizing radiation; in fact, the high density of the deliv-
ered dose makes a double breaking event quite probable. The latter occurs when the
second radiation damage is dealt before the first can be repaired. This most likely oc-
curs in the presence of a high dose rate. The relationship between dose and number of
double breakage has been experimentally sought; the model more accepted is the linear
quadratic. It seems that a double chain breaking cannot be repaired or possibly can be
repaired by an ”error-prone” mechanism.
1.4.2 Cell survival curves
After a single dose of ionizing radiation, the number of living cells (surviving fraction)
decreases with increasing dose. The graphic expression of this phenomenon is the cell
survival curve.
The typical survival curve for mammalian cells has a ”shoulder” at low doses and
becomes exponential only for higher doses. The parameter D0 determines the slope of the
linear part of the curve and indicates the dose which reduces the surviving fraction to a
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factor equal to 0.37. The number of extrapolation N, which is obtained by extrapolating
the linear portion of the curve until it intersects the y-axis, is an index of the cell’s ability
to store and repair the sublethal damage and it represents the number of targets to hit
to produce cell death. Typically D0 has values between 1-2 Gy and N between 1 and 5.
The width of the shoulder is indicated by a parameter Dq (quasi-threshold dose), which
is the intersection between the extrapolation of the straight portion of the curve and the
horizontal line passing through the 100% of survival.
Figure 1.4: Cell surviving fraction as a function of dose. It clearly shows the initial
shoulder [42].
To interpret the behavior of survival curves in which a shoulder is present, a theo-
retical model was developed based on the assumption that inactivation of a cell requires
the inactivation inside the cell of a number n ≥ 1 of targets, each of which requires a
single shot to be inactivated (hypothesis of multiple targets single-shot). The inactivac-
tion of the cell occurs only when a number of a sublethal events occur within a short
period of time. At low dose, only a few events per cell will occur, thus making cell death
unlikely. There will be a dose range in which inactivation is not experienced (part of the
shoulder). At higher doses, interaction events within cells begin to add up, until the first
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inactivations occur, the survival curve will begin to trend downward (passage between
the shoulder and linear region). Increasing the dose further, the number of events per
cell will keep growing, tending to be n-1 in each of them. Above this dose the behavior
is identical to a system of elements inactivable with a single hit, since a single additional
event per cell will reach the N threshold and will cause inactivation.
The analytical expression corresponding to this theoretical model is the following:
f = 1− (1− e−
D
D0 )N (1.6)
This model implies a zero slope at very low doses, but experimental data are often not
in agreement with it. It is possible to modify the simple multitarget model to improve
the shape of the curve in the low-dose region, by ,ultiplying the multitarget term by a
single-target term (two component model), obtaining the following analytical expression:
f = e
− D
D1 [1− (1− e−
D
D2 )n] (1.7)
A model widely used in radiotherapy is the linear quadratic, where the fraction of sur-
viving cells is:
f = e−(αD+βD
2) (1.8)
D is the dose, α and β are two costants that mean:
• α: log of cells killed per Gy, is the constant of proportionality linearly linking the
cellular lethality to single hit damage;
• β: log of cells killed per Gy2, is the constant of proportionality quadratically linking
the cellular lethality to damage due to the sum of sub-lethal events.
The ratio α/β is the dose in Gy at which lethality is equally likely to be due to a single
events and to an accumulation of sublethal damage.
The component αD represents a non-repairable damage (the dose/effect relationship
is linear, from a single shot, and therefore even small doses are able to cause damage),
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while the component βD2 indicates the existence of recovery process (more hit events),
the dose should increase quadratically to surmount them.
In the case of fractionated irradiation, figure 1.5, at each subsequent irradiation
reoccurs the shoulder, because of the repair of sublethal damage by the elements of
the system. The overall dose, necessary to obtain the same degree of cell inactivation,
must be increased by Dq times the number of fractions -1. The fractionation of dose
in radiotherapy involves a ”therapeutic gain”, in fact, it increases tollerance in normal
tissue (due to repair of damage induced by radiation) and, at the same, time eliminates
the radioprotective effects of hypoxia on tumor (due to reoxygenation phenomena).
Figure 1.5: Fractionated irradiation: the overall dose is given by Df = Du + (n− 1)Dq,
where n is the number of fractions.
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1.4.3 Radiation quality
Although all ionizing radiations interact with living matter in a similar manner, different
types of radiation differ in their effectiveness, or ability to do harm to a biological system.
The various radiations, in fact, interact with matter in a different way in relation to the
amount of energy deposited along their path.
The transfer of energy of radiation is defined by LET (linear energy transfer) and
denoted by the symbol L∆, [3]
L∆ =
(dE
dl
)
∆
where dE is the local energy loss due to collisions for a charged particle along a track
segment dl, considering only collisions involving transfer of energy less than ∆(ineV ).L∆
is abitually expressed in KeV · µm−1, if ∆ = ∞ all energy losses are considered. High
LET means high specific ionization, and is not connected to the energy because some
particles can have an high LET at low energy and a low LET at high energy.
• Low-LET radiations have a track with primary events (collisions) well separated
in space; it is the case of X-rays which are said to be sparsely ionizing;
• High-LET radiations have tracks with primary events very close in space. It is the
case of ions and heavy particles which are said to be densely ionizing.
A different LET leads, at equal doses, to different biological effects and in order to take
this fact into account the Relative Biological Effectiveness, RBE, has been introduced.
The intent is to quantify the effect, at the same imparted dose, of radiation r in com-
parison with reference radiation which is assumed to be X-rays at 250 KeV. By this
definition, the reference radiation has RBE equal to 1; this way it, quantifies the incre-
ment of biological effects of highly ionizing radiations with respect to X-rays at the same
physical dose.
Its follows: the RBE of some test radiation (r) compared with X-rays is defined by
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Figure 1.6: Comparison of ionization density depending on radiation LET [42].
the ratio [7]
RBE =
D250
Dr
where D250 and Dr are respectively, the doses of 250 KeV X-rays, and of the test radiation
required for the equal biological effect. The higher the LET, the higher the RBE, as it
is shown in figure 1.7 for radiation of different LET. RBE increases with increasing LEt
up to a certain maximum. If the LET is further increased, far fewer tracks are required
to deposit the same dose, leading to saturation of the effect and eventually to decrease
of RBE with increasing LET [8].
Since prescribed doses to the target, dose constraints to critical structures and frac-
tionation schemes are largely based on clinical experience gained with photon therapy,
prescription doses for proton therapy are also defined as photon doses. Therefore, the
RBE adjusted dose has been introduced, defined as the product of the physical dose
and the respective RBE. Before 2008 proton doses were given in Cobalt Gray Equivalent
(CGE), and then it was changed to reporting DRBE as Gy(RBE) [9]. Most proton ther-
apy treatment facilities have adopted a generic RBE of 1.1. This value is mainly based
on animal experiments performed in the early days of proton therapy [10] However, dif-
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Figure 1.7: LET at which the RBE reaches a peak is the same (about 100 KeV/µm)
for a wide range of mammalian cells, as the LET increases, RBE increases slowly at first
and then more rapidly, with LET level beyond 10 KeV/µm. Over 100 KeV/µm, the
RBE again falls to lower values, as the densely ionizing radiations produce easily and
often a DSB, but energy is ”wasted” because ionization events are too close together and
produce an overkill effect.
ferences in biologcal effect occur not only between X-rays and protons, but also between
protons at different energies, as well as depth of penetration, biological endpoint, dose
per fraction, position in the SOBP and particulr tissue. nevertheless, there are no clinical
data indicating that the use of a generic RBE of 1.1 is unreasonable.
1.5 Accelerator
The instrument used in proton therapy is mostly the same that are used for nuclear
physics: accelerators, detectors and Monte-Carlo simulation. A particle accelerator is
a machine that aims to produce ions or particles beam at high energy. There are two
principal kinds of accelerators: cyclotrons and synchrotrons. In this thesis only cyclotron
will be taken into account, because at the moment it is the only accelerator used in proton
therapy.
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1.5.1 Cyclotron
The cyclotron is a kind of particle accelerator, developed by Ernest Lawrence in 1932,
where charged particles are accelerated from the center to the external part following a
spiral path. The trajectory is induced by a static magnetic field and the particles are
accelerated by an oscillating electric field.
The idea is to make protons circulate inside two hollow electrodes, one with a ”C”
shape and the other with a ”D” shape, both inserted between two poles of a magnet.
A representation of a cyclotron is visble in Figure 1.8. Every half round protons are
Figure 1.8: Structure of a cyclotron and path of protons inside it.
accelerated by the alternating voltage applied between the electrodes: thanks to the
combination of an electric and a magnetic field (acceleration and deflection), the proton
beam will follow a spiral trajectory. The main advantage of this accelerator is that it
permits to reach higher energies with a smaller machine and with lower tension compared
to normal electrostatic accelerator.
Protons are inserted exactly at the center of the cyclotron at low energies and gaseous
hydrogen ionized by an electric discharge is used as source. As said before the energy of
proton beam will increase every half loop, as it will encounter on a potential difference
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between the two electrodes that will accelerate it, this potential difference will be flipped
when protons will be again close to the next half loop so that they will increase energy
again. To extract the protons there will be a deflector that will permit the beam to
proceed out on a line, creating the real beam [11].
Equations that regulate how cyclotrons work are well known: FC the centripic force,
for non-relativistic particles, necessary to keep them in a circular orbit is:
FC =
mv2
r
where m is the mass of the particle, v it’s velocity and r the radius of the trajectory.
This force is due to Lorentz’s force f − b of the magnetic field B:
FB = qvB
with q that is the charge of the particle. The maximum energy is reached at the ex-
tremity of the electrodes, where the radius is r = R (R is the radius of the electrodes).
Combining the two forces and knowing that the kinetic energy is: K = 1
2
mv2 is it easy
to find that the kinetic energy of the beam is:
K =
q2B2R2
2m
.
Alternating voltage frequency depends on the cyclotron’s resonance frequency ν that is
ν =
qB
2πm
.
Important evidence emerging by the last equation is the independence of ν by the radius.
This behaviour is true when we deal with a non-relativist particles speed.W when the
ratio β = v/c start to grow we have to consider that mass is no more constant, but it
became the relativistic mass
m =
m0√
1− β2
= γm0
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γ is called relativist factor and is shown in Figure 1.9. Therefore the new frequency of
resonance will now depends also on the speed of the particle:
ν =
ν0
γ
= ν0
√
1− β2.
This effect is not negligible for proton therapy, because for deep tumors protons used
have energy around 200 MeV to which correspond β = 0.55. Cyclotrons that consider
this correction are called synchrocyclotrons.
The beam produced by a cyclotron has always the same energy, that is, in therapeutic
cases, approximately 230-250 MeV, and a fixed frequency of pulsation, around 10-20 ns.
An Energy Selection System reduces the energy through the insertion of some absorber,
to reach the energies necessary to hit target always less deep (it requires generally between
50 and 100 ms). The interaction between the beam and the absorbers produce nuclear
reactions that generate a radioactive area around the patient, especially if the energy
has to be reduced a lot.
Figure 1.9: γ in function of β.
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Chapter 2
PSI status and planning dose
2.1 PSI facilities
The Center for Proton Therapy (CPT) at Paul Scherrer Institut (PSI) is in operation
since 1984, with more than 8000 patients treated. Furthermore, since 1996 the center
introduced the pencil-beam scanning technique for treating large and deep seated tumors,
as for example chordoma and chondrosarcoma of the skull base or along the spinal cord.
In fact, PSI has developed the worldwide first compact scanning gantry for the irradiation
of deep seated tumors with proton beam.
The entire proton delivery ficility is shown in Figure 2.1. The Core of the facility is
COMET, a 250 MeV superconducting cyclotron where the protons are accelerated. The
beam is then deflected by means of electromagnetic switches to one of the four therapy
stations (Gantry 1, Gantry 2, Gantry 3 and OPTIS 2), within less than a thousandth of a
second. Hardware and software for control and safety systems of Gantry 1, Gantry 2 and
OPTIS 2 have been completely developed at PSI. Gantry 3, that has same capabilities as
Gantry 2 on a technical level, has started treatments in June of 2018 and was developed
by Varian, as well as the software to use this gantry.
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Figure 2.1: Illustration of the facility for proton treatment at CPT, in PSI: the cyclotron
COMET, OPTIS 2, Gantry 1, Gantry2 and Gantry 3 [26].
2.1.1 OPTIS 2
OPTIS 2 (figure 2.2) is dedicated to treatment of ocular tumors using the passive scatter-
ing technique with a fixed horizontal beamline. It is a newer and more advanced version
of its ancestor facility, OPTIS 1, that has been in operation from 1984 to 2010.
The patient is seated in a treatment chair facing the nozzle with head immobilized
using an individualized mask and a bite block. The chair is mounted on a hexapod
robot allowing the positioning of the patient with 6 degrees of freedom. For allowing
the localization of the tumor during the treatment with sub-millimeter accuracy, several
small clips are suturated on the sclera (eye surface) in the proximity of the target during
a previous surgical operation. For positioning the patient in the most accurate way,
OPTIS 2 uses two X-rays, aligned with the treatment isocenter so to provide orthogonal
images of the eyes of the patient. The patient has to fix a LED light throughout the
treatment, whose position is optimized at the time of planning as a compromise between
patient comfort and best entrance direction of the beam, in order to cover in the best
way the extension of the tumor, while sparing as much as possible eyelid and pupil.
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Intrafractional motion of patient eye is monitored using beam’s eyes view camera.
As eye tumor is shallow the energy used for this type of tumor is 70 MeV. However,
during the energy degradation from 250 MeV (energy given by cyclotron) more than 99%
of the original protons is lost. For that reason, in order to ensure a higher efficiency of
transport, a double-scattering process is implemented in OPTIS 2. The extracted beam
passes through a range shifter, used for setting the range and ensuring pre-scattering
of proton pencil beam and ensures homogeneous field at isocenter. Depending on the
needed ranges, 9 scatter foils are available. The Spread-Out Bragg Peak is then realized
using dedicated modulator wheels. The maximal diameter of the circular field is 35 mm,
reduced for each patient using individually milled copped collimator aperture.
Figure 2.2: OPTIS 2 Facility at PSI [26].
2.1.2 Gantry 1
Gantry 1 (figure 2.3) is the first facility worldwide that used active scanning technique
for treatments of deep-seated tumors. It has been operational from 1997 until January of
2019, treating tumors located mainly in the skull, spinal cord and in the pelvis. Future of
this gantry is still under decision and it will be probably used for biological and clinical
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research.
The transverse movements of the pencil beam are done with a fast scanning magnet
and patient-table motion respectively, while the third dimension (depth) is varied adjust-
ing the beam range. To do that, 40 range-shifter plates of polyethylene are placed into
the beam path by means of a pneumatic system, at the nozzle level. To ensure quality
and safety of delivery, the beam is monitored in the nozzle using two plane-parallel ion-
ization chambers for checking the dose, a strip chamber for controlling in two dimensions
position and width of the beam.
The weak points of Gantry 1 were [12] :
• the unsatisfactory access to the patient table when the beam is applied from below;
• the slow speed of scanning, that is a limitation for applying repeatedly target
repainting and, this makes the treatment of moving organs not really possible on
this gantry.
Figure 2.3: Gantry 1 Facility at PSI [26].
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2.1.3 Gantry 2
The positive experience of using the scanning technique brought in the year 2000 the
decision of PSI to expand and upgrade the facility. It is in the frame of this new project,
called PROSCAN, that the realization of Gantry 2 was planned. Treatment in this
gantry (Figure 2.4) started in 2013. The design of the Gantry 2 is derived from the
practical experience of using Gantry 1, but is substantially improved and renewed.
For what concerns the layout, Gantry 2 has a larger diameter, of 7.5 m (isocentric),
compared to the 5 m (eccentric) of Gantry 1.
The major improvement concern the speed of the beam delivery. In fact two high-
speed magnets (scanning speeds of 2 cm/ms and 0.5 cm/ms for the two axes) are used
to scan through the tumor in two dimensions. This double scanning and the isocentric
layout permit comfortably large space around the couch, thus fast and easy access to the
patient table. The depth of penetration of the protons can change from one tumor layer to
the next one in about 100 ms (80 ms for 3 MeV energy changes). That approach permits
to generate dose distributions less sensitive to organ motion and allows to implement
repainting. Moreover, on this machine both discrete and continuous line scanning can
be applied [13]. However, for now, only the discrete approach is used on patients.
In addition, the components in the nozzle are designed to have as little materials as
possible along the beam path. This maintains a small spot size at all energies (width
lower than 4 mm for 100-230 MeV). The nozzle can be also extended to reduce the air gap
between the beam line exit window and the patient, mitigating in this way the angular
spread of protons. An electronically controlled range-shifter of 4 cm water-equivalent
thickness is mounted within the nozzle and can be remotely positioned into the beam
to allow the delivery of Bragg peaks close to the patients surface (proton’s energy lower
than 70 MeV) [14].
Further notable development is the in-room imaging: a sliding CT scanner, used for
treatment planning and for the daily verification of the patient position. This allows
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to reach the CT in a single movement of the patient table. Moreover, another X-ray
system is mounted on the gantry itself, which takes images in the direction of the proton
beam, the so called ”beam’s eye view”. Thanks to its fluoroscopy capability, it pro-
vides increased precision and quality assurance, in particular in the treatment of moving
tumors.
Figure 2.4: Gantry 2 Facility at PSI, the picture includes also the dedicated CT scanner.
[27].
2.1.4 Gantry 3
The gantry design is based on Varian technology, which has been combined with advanced
PSI active scanning technology. In fact a major challenge with gantry 3 was the link of
the existing PSI PROSCAN system with the Varian ProBeam system, while retaining the
system integrity and high performance level. An additional problem was the installation
and commission of Gantry 3 while keeping the other treatment room in full operation.
Mechanically, Gantry 3 is an implementation of the ProBeam Gantry by Varian [15].
It rotates over 360◦ and has a total weight of 270t. The rotating parts have an envelope
diameter of 10.5 m and a length of 10 m. The beam is deflected from rotational axis by 45◦
dipole and bent towards the iso-center through a 135◦ dipole. Five quadrupoles and three
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Energy range 70-230 MeV
Energy precision < 0.1 MeV
Beam momentum spread < 1 %
Layer switching time 200 ms
Beam FWHM at IC (in air) 8.5 mm
Lateral beam position precision Iso-Center (IC) 1 mm
Field size 300 x 400 mm2
Dose delivery 2 Gy/liter/min
Table 2.1: Gantry 3 Main Performance Specification [16]
orbit correction magnets are used to set the beam optics. Two additional quadrupoles
have been introduced at the entrance to the Gantry in order to facilitate beam matching
between PSI and VMS beamlines and to enhance the transmission through the Gantry
beam transport system.
Gantry 3 is a downstream, divergent raster scanning system. The scanning magnets
are placed after the last 135◦ dipole and allow a maximum field of sized 30 x 40 cm.
One major goal for Gantry 3 was to achieve overall system performance comparable
to Gantry 2. Table 2.1 lists the main performance parameters of Gantry 3. One of the
main development achieved thanks to the collaboration with Varian has been an energy
layer switching time of 200 ms; it includes modifications on the beamline hardware as
well as adaptations and new developments on the control system side.
Gantry 3 has been equipped with a 360◦ co-rotating X-ray system. A further devel-
opment was the upgrade of the X-ray system to a cone beam CT (CBCT). Gantry 3 is
shown in Figure 2.5. The first patient has been treated in June 2018 and the gantry is
actually perfectly working at full capacity.
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Figure 2.5: Gantry 3 Facility at PSI [26].
2.1.5 COMET
In May 2001, PSI signed a contract for the delivery of a new cyclotron, named COMET,
Figure 2.6). It is based on a design of Blosser, NSCL, (USA) and has been manufactured
by ACCEL Instruments GmbH (D), in close collaboration with PSI. The cyclotron has
been delivered in March 2004 and the first beam was extracted one year later. After a
period of machine tuning, commissioning and acceptance tests, the cyclotron has been
accepted by PSI in 2006.
The cyclotron accelerates protons to a fixed energy of 250 MeV. The 3.8 T magnetic
field is provided by super conducting coils. The high extraction efficiency of at least 80%
[17] is an important routinely fulfilled specification that has never been achieved before
in compact cyclotron of this energy. This minimizes the amount of radioactivity in the
machine and thus allows a relatively short waiting time for service. At PSI rigorous beam
dynamics calculations have been performed during design phase, to study the effect of
possible misalignments of magnetic coils and the effect of betatron resonances on beam
losses [18]. These studies were very helpful to understand and minimize the beam losses
observed in the start up phase. Afterwards, work focused on increasing the degree of
automation of the control system and on improving of the stabilization of the beam
intensity in the kHz range.
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Figure 2.6: A view of the cyclotron COMET used at Paul Scherrer Institute [26]
2.2 Planning dose
Proton therapy provides a tool for delivering highly conformal dose distributions, since
protons show the attractive physical characteristic of having a well-defined range, beyond
which no energy is deposited. However, the resulting proton dose distribution is strictly
related to the technique used for the delivery, as well as the type of treatment plan
defined on the patient.
2.2.1 Beam delivery systems
After the protons have been accelerated, either by a cyclotron or a synchrotron, they are
transported into the treatment room through the beam line. The output proton beam is
mono-energetic with a diameter of only few millimeters. Clinical use of the proton beam
requires both spreading the particles to a useful uniform area in the lateral direction, as
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well as creating a uniform dose distribution in the depth direction. The main function
of the treatment head, also called nozzle, is shaping the proton beam into a clinically
useful 3D dose distribution [3]. Two modalities of beam spreading are used: passive
scattering [19] and active scanning [20] (see Figure 2.7). With the last approach, the full
potential of protons can be exploited as the Bragg peaks can be deposited anywhere in
three dimensions within the tumor volume.
Figure 2.7: Schematic diagrams of passive scattering and active scanning techniques [28].
Passive scattering
Passive scattering is a delivery technique in which range shifting and scattering materials
spread the proton beam.
In order to have a uniform dose region the depth direction, Bragg peaks are shifted
in depth and given appropriate weight, so that a Spread Out Bragg Peak (SOBP) is
created by combining these proton beams of decreasing energy. This method of adding
pristine peaks is called ”range modulation”. Depending on the size of the target to be
36
covered, the extent can be adjusted by changing the number of peaks. There are three
principal range modulation techniques:
• Energy stacking: it is the easiest method because no dedicated nozzle elements
are required since the energy of the protons is changed at the accelerator level.
This can be achieved either by changing the extracted synchrotron energy or the
energy-selection system setting at the exit of the cyclotron.
• Range modulator wheels: this method has been proposed by Wilson in his original
article about proton therapy [1] and continues nowadays to be the most common
approach in clinical proton-scattering systems. A range modulator wheel has steps
of varying thickness and a certain angular frequency. Each step corresponds to
a certain Bragg peak, that is irradiated sequentially during the rotation. The
thickness of a step determines the range shift of the related pristine peak, while its
angular width affects the number of protons hitting the step, thus the weight of
the peak.
• Ridge filters: it is a stationary device composed of tens of bars, where each bar
has the same ridge shape. The range of protons in a spot is modulated according
to the position they pass through, resulting in the broadening of the Bragg-peaks.
The principle is the same as the modulator wheel: thickness and width of the steps
determine respectively the range and the weight of the peaks.
The uniformity of the dose along the lateral dimensions is instead achieved thank to
designed specifically scatters. The simplest scattering system is a single, flat scatterer
that spreads a small proton beam into a Gaussian-like profile. Typically the scatters are
high-Z materials, e.g. lead and tantalum, providing the largest amount of scattering for
the lowest energy loss. Due to its low efficiency, defined as the portion of protons inside a
useful radius, this approach is limited to small fields with a diameter lower than 7 cm [3].
To overcome this limitation, a double scattering system can be used to scatter more of
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the central protons to the outside and create a flat profile. Usually a flat scatterer spreads
the beam onto a contoured one, so that the profile is flattened at some distance. Since
this contoured scattered is thick in the center and thin on the outside, protons hitting
the center lose more energy than those going through the periphery. For that reason,
normally the high-Z scattering material is combined with low-Z compensation material,
e.g. plastic, with thickness designed to provide constant energy loss, while maintaining
the appropriate scattering power variation. Hence, the thickness of scatterer decreases
with distance from the axis, whereas for compensation material the thickness increases.
If the energy compensated contoured scatterer is used, the energy of the protons needs to
be increased in order to achieve the same range in the patient as with an uncompensated
scatterer.
Finally, to confirm the dose to the target, field-specific apertures and range compen-
sators are used. The first ones block the beam outside the target and adjust the beam
laterally, while the compensator is a variable range shifter that conforms the beam to
the distal end of the target. This conformity is in 2D, as the SOBP is constant and equal
to the maximum required to cover PTV.
Active scanning
The principle of active scanning proton therapy have been first proposed by Kenai et al.
in 1980 [21] and is strictly connected to the fact that protons are charged particles, thus
can be deflected by magnetic fields. This approach was clinically implemented first at
PSI, where patients have been treated since 1996 on a fully rotational treatment gantry
[22]. In active scanning, also called Pencil Beam Scanning (PBS), the beam transported
to the nozzle is directly sent to the patient without interacting with any scattering or
energy-modulation devices. Active Scanning has proven to be very good for clinical
treatment as it modulates the dose in 3D, also proximal to the tumor, and not in 2D as
for passive scattering.
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This technique consists of the superposition of individual Bragg peaks positioned in
3 dimensions inside the tumor’s volume. The 3D allocation of these peaks is in general
performed thanks to sweep magnets. However, the mechanical configuration can be
different depending on the gantry. The first one uses one sweep magnet only and the
movement of the couch, while the latter one exploits magnets along 2 dimensions. The
third dimension is instead covered by changing the energy of the beam. For a synchrotron
it can be simply varied changing the applied fields, while in case the accelerator is
a cyclotron a degrader at the exit must be used. Moreover, range-shifter within the
nozzle allows the delivery of Bragg peaks close to the patient surface. This expedient is
introduced in order to have a proton beam with sufficient intensity, condition unreachable
using the degrader only.
In traditional active scanning, namely discrete spot scanning, the dose is applied in
discrete steps both laterally and in depth, with each position typically being called a
spot. When the beam is on this spot is static and, after each spot, the beam is switched
off and the magnetic and/or energy settings are changed to move to the next spot. The
time required for these changes is called dead time. As a consequence of this, the total
treatment time is substantially longer than the actual beam-on time, in which dose is
delivered. A reduction in dead time can be achieved by scanning the beam continuously,
at least along one of the axes in lateral plane. This concept leads to another modality
of PBS, called continuous line scanning. By modulating the scanning speed and the
beam intensity, it is possible to apply almost arbitrarily complex, inhomogeneous proton
fluences along each line. In this mode, position and dose checks are either performed
during irradiation, after scanning a single line or after each isoenergy layer. Continuous
line scanning can be considered as a superposition of an infinite number of spots on a
scanning grid with an infinitesimal spacing [13].
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2.2.2 Treatment plans
Typically, two major categories of plans can be delivered, namely Single Field Uniform
Dose (SFUD) and Intensity Modulated Proton Therapy (IMPT) plans [23] [24]. The
first method can be delivered with passive scattering as well as by means of pencil beam
scanning, while IMPT is restricted to active scanning only.
For both SFUD and IMPT with PBS, the treatment planning system considers pencil
beam Bragg peak explicitly, rather than their combinations of any type as for scatter-
ing, and the quality of the beam is determined largely by the quality of the individual
pencil beam [23]. The specification of treatment beam is basically a list of Bragg peaks,
each with the energy of the protons, the lateral location of the peak projected onto the
isocenter plane, and the number of protons often given in the unit of Giga-protons [3].
SFUD plans
In treatment planning of proton therapy for Single Field Uniform Dose, each field is
composed of different Bragg peaks with weights optimized in such a way that the single
field dose distribution in the target is homogeneous. The plan is obtained by a linear
combination of individually optimized fields, which improves the dose homogeneity in
the tumor, while distributing the entrance dose on a larger surface (Figure 2.8).
This approach essential arises from passive scattering delivery, since also in this case
the delivered SOBP applies a uniform dose across the target. However, there are few
notable differences in particular the active scanning approach adds some flexibility, al-
lowing both distal and proximal conformity for a single beam, thanks to the fact that
range and modulation width are set on a per-proton-ray-beam basis [3]. For this reason,
SFUD with active scanning can be considered more efficient as only Bragg peaks are
delivered within, or close to, the target [25].
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Figure 2.8: Example of SFUD plan. The critical structure is contoured in red. Picture
taken from A.J. Lomax PTCOIG teaching course.
IMPT plans
In treatment planning of proton therapy for Intensity Modulated Proton Therapy, also
called Multi-Field Optimization (MFO), the desired coverage of the target with homo-
geneous dose is achieved only by combination of two or more treatment fields, each of
which can deliver a highly inhomogeneous dose distribution to the target (figure 2.9).
The resulting plan is given by the simultaneous optimization of all Bragg peaks from all
fields.
With this technique, the weight of the spots is optimized taking into account also
the dose to healthy tissue and Organs At Risk (OAR) close to or embedded in the
target. Depending on the anatomy and field direction, certain parts of the target can be
irradiated only by certain fields. Moreover, another difference in this approach is that
the uniform single field constraint is removed and to the optimizer is given full reign to
weight Bragg peaks regardless of the final shape of the individual field dose distribution,
as long as the total dose, sum of all the individual field dose distributions, gives the
desired result. For these reasons, the IMPT approach best exploits the full potential
of scanned proton therapy, in fact it provides even more flexibility in tailoring the dose
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distribution to the target and in selectively avoiding critical structure [25].
Figure 2.9: Example of IMPT plan. The critical structure is contoured in red. Picture
taken from A.J. Lomax PTCOIG teaching course.
2.3 4D theory
Anatomy can change significantly with time both during and between radiation treat-
ments. Intrafraction anatomic motion deformations occur because of the respiratory,
digestive and cardiac systems. Interfraction motion and deformation occur because of
tumor shrinkage or growth, translations and rotations of the target within the skeletal
anatomy. These temporal anatomic changes are not explicitly accounted for with stan-
dard conformal proton therapy or IMPT approaches. Moreover, imaging, planning and
delivery errors can be introduced by not explicitly accounting for respiratory motion.
If respiratory motion is not accounted for during computed tomography image acqui-
sition as is the case when conventional proton therapy techniques are applied in thoracic
and abdominal sites, this motion causes artifacts during image acquisition. These ar-
tifacts cause distortion of the target volume and incorrect positional and volumetric
information [29].
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During treatment planning margins need to be large enough to ensure coverage of the
target at the full extents of motion. Generally, for CT-planned lung cancer treatments,
the Gross Tumor Volume (GTV) is outlined, from which a margin is added to include
the suspected microscopic spread (which added to the GTV creates the so-called Clinical
Target Volume (CTV)). Obtaining the Planning Target Volume (PTV) from the CTV
involves the addition of the internal margin and the setup uncertainty margin. The
internal margin by definition includes both intrafraction (because of respiration) and
interfraction motion. Accounting for respiratory motion adding treatment margins to
cover the limits of motion of the tumor is clearly undesirable because this increases
the volume of healthy tissues exposed to high dose. This increased treated volume
increases the likelihood of treatment-related complications. However, if the margins are
not sufficiently large, part of the CTV will not receive adequate dose coverage.
A method to alleviate the respiratory motion problems is to use 4-dimensional (4D)
or tumor tracking proton therapy. 4D proton-therapy can be defined as ”the explicit
inclusion of temporal changes in anatomy during imaging, planning and delivery of proton
therapy”. Note that this covers both intrafraction and interfraction motion issues.
In principle, 4D proton therapy is intuitive and simple. However, in practice, 4D
proton therapy is a very difficult problem, with many levels of complexity. It will be
discussed later the aspects of imaging and planning in 4D therapy. It is important to
note that respiratory gating and breath hold techniques can achieve same goals as 4D
proton therapy [30] [31].
2.3.1 Rationale for 4D proton therapy
Lung cancer has a poor prognosis. The estimated 5-year survival for lung cancer patients
is 15% [32]. However, there is strong clinical evidence that higher tumor doses result
in a survival advantage for lung cancer patients and also that lower lung doses result in
reduced lung complications as expanded on later.
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Thus, there is clinical evidence that technologies, such as 4D proton therapy, which
through safe PTV volume reduction will allow an increased dose to the tumor while
sparing healthy tissue can improve balance between complications and cure.
2.3.2 4D CT Imaging
The advantage of 4D over 3D CT imaging is that not only the motion artifacts are
reduced, but the tumor and organ motion information is also encoded in the 4D image
set. [33] A schematic diagram of the 4DCT image acquisition and planning process is
shown in Figure 2.10.
The patient is CT scanned using a spiral technique. As the patient is scanned, the
respiration signal is simultaneously acquired. Once the images are acquired, they are
postprocessed into individual 3D image sets according to the respiratory phase at the
time each image was acquired. Because many 3D CT scan sets constitute a 4D scan,
more slices are necessarily acquired. This increase in the number of slices raises issues
with patient dose, CT tube heating and data management.
Breath should be as much as possible regular. Irregular respiration, particularly
variations in amplitude between breathing cycles, makes the acquisition of high-quality
4DCT extremely difficult.
Rather than sorting images into their respective phase bins, retrospective image re-
construction techniques, which operate in sinogram space rather than image space, allow
improved temporal resolution for 4DCT. A technique that is emerging in these years is
4D cone beam CT, that allows a full thoracic CT scan to be performed in only a few
respiratory cycles. Another interesting future development is combined 4DCT/Positron
Emission Tomography (PET). The combination of 4DCT with 4DPET holds significant
promise for lung cancer proton therapy imaging and treatment.
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Figure 2.10: A flow chart of the 4D-planning process. [33]
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2.3.3 4D treatment planning
Once the 4D CT scans have been acquired, the next problem is how to use the data
for treatment planning. Because the amount of data is of the order of 10 times those
for a standard CT image set, there is an order of magnitude increase in the amount
of work required to obtain a 4D treatment plan. As, this increase in workload is so
large, 4D planning requires automation. The tool that facilitates the automation of
the 4D planning process is deformable image registration [34]. This technique allows the
volumetric mapping of 3D CT image set in one respiratory phase to another phase. Once
these transformations between breathing phases are known, processes such as anatomic
contour definition, treatment planning and treatment evaluation on multiple data sets
can be automated. With this automation, the workflow from a user interaction point of
view is similar for 3D and 4D.
The anatomy (OAR) and tumor) drawn on the reference CT is mapped to the CT
scans of the other phases using the deformable registration transformation matrices,
which creates automatically contours. Deformable image registration is not an exact
science and errors will be introduced in the process. A (crude) method of verifying the
validity of the transformation is to visually correlate the automatically created contours
with the CT anatomy itself.
Because 4D radiation delivery accounts for the change of tumor position with time,
the concept of a 4D PTV naturally appears, called Internal Target Volume (ITV). The
parallel appears between rescanning and replanning patient midway through the treat-
ment course to account for interfraction motion, where clearly different PTV would be
created for the subsequent plan change with time. This rationale can be applied to the
case of intrafraction motion, where a distinct PTV associated with each respiratory phase
is created as both the CT geometry and treatment plan change with time, although over
a much shorter time period. Once the anatomy has been defined, the treatment beams
are added.
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2.3.4 Motion mitigation
There are many ideas of how to mitigate effects due to temporal changes in anatomy.
Such changes can be taken into account during planning simply through the use of the
ITV approach [35] or using the more sophisticated approach of 4D-inverse planning [36].
Alternatively, treatments planned on a static geometry can be delivered in a way that
compensates for changes of the anatomy. This approach is followed in beam rescanning,
gating, and tracking. For the three latter techniques, the common expectation is that
none of the methods represents the ultimate solution. Rather, different approaches have
different advantages in different scenarios. Many of the motion management strategies
rely on motion information acquired prior to the actual treatment (for example, 4D CT).
In this case, one should always be aware that 4D CTs only provide a snapshot of the
present motion and the resulting uncertainties at the time of treatment should be taken
into consideration. The parameters which should be considered in the choice of the
motion management approach include the following:
• the facility specifications such as scanning speed (energy modulation speed, time for
lateral position adjustment, and dose rate), the available scanning method (raster-
scan, spot-scan, and continuous scan), the deliverable dose resolution, the time
latency (in actively controlled beam delivery), and the available imaging tools;
• patient specific parameters such as the target volume and location, surrounding
critical structures, motion parameters, clinical status, and patient compliance, and
the fractionation scheme used.
Below, the current status of motion management approaches in particle therapy is sum-
marized and areas for future investigation are identified.
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Margin-based approach
The use of margins alone for motion management is likely not sufficient for scanned
particle beams because of interplay effects [37]. Nonetheless, margins and ITVs could
be required also for scanned particle beam treatments since some motion management
techniques are of limited precision and thus margins have to cover for the uncertainties.
This is especially important for rescanning which does not perform any surveillance of the
patient’s motion and thus relies on margins. Implementation of the ITV, or any margin
approach, using concepts defined for photon beams may well be invalid for protons and
heavy ions due to the high sensitivity of the dose distribution to density variations in
the entrance channel.
Rescanning
With rescanning [38], the ITV/PTV is irradiated multiple times within each field delivery,
with the rationale that interplay effects will be smoothed out and thus a homogeneous
coverage of the CTV is achieved. However, this will inevitably be at the cost of the
therapeutic dose in the internal margins that form the PTV. Multiple delivery modes
for performing rescanning exist, with the most prominent distinction being whether the
scans are first repeated within a 2D energy layer (slice-by-slice rescanning) or the whole
3D volume is rescanned (volumetric rescanning). In both modes, different repainting
strategies can be employed as, for example, scaled rescanning, for which the beam weight
of each scan position is divided by the number of rescans or isolayered rescanning, for
which fixed beam weights are applied per rescan. When implementing rescanning, par-
ticular awareness has to be given to machine specifications such as the scanning speed,
the scanning method, and the dose deliverable resolution which can place limitations on
the rescanning approach.
For the determination of the appropriate repainting strategy, the fractionation scheme,
number of fields, as well as the number and temporal sequence of the energy layers con-
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tributing to a beam position should be considered. For a single-field-uniform-dose plan,
all of these parameters have been shown to contribute an intrinsic rescanning effect,
which should be considered in the decision of how many rescans and what type of res-
canning should be employed. Extensive simulations and experimental work are required
to comprehensively evaluate these effects for different patients and plan parameters.
Synchronization effects due to the periodicity of target motion and individual rescans,
especially for repetitive scaled rescanning, are a potential source of large underdosage in
the CTV [39]. Their impact has to be studied more extensively and possible solutions,
such as the introduction of random pauses between rescans, have to be investigated.
Gating
Gating refers to an irradiation technique in which the beam is turned on during specific
motion phases only, the so called gating window [40]. Gating thus requires a motion
monitoring system that determines the motion phase of the patient during treatment
delivery. A review on motion monitoring methods was given by Murphy [41]. Gating
has been used for treatment with scattered particle beams for several years. For applica-
tion to scanned beams, the residual motion within the gating window and the scanning
process interfere, leading to a residual interplay effect. To mitigate this interplay effect,
a combination of rescanning and an increased overlap between neighboring pencil beams
have been proposed.
With respect to treatment planning, gating requires optimization of gating window
size and the parameters that mitigate the dosimetric effect of the residual interplay.
Robustness analysis to investigate the effect of baseline drifts, limited precision of the
motion monitoring system, and change in patient breathing parameters are also required.
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Part II
Experimental Work
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Chapter 3
Analytical results
The CPT at PSI recently started treating moving tumors, using pencil beam scanning
in the regime of volumetric rescanning. Rather than delivering dose per fraction at once,
the dose of each spot is divided into smaller parts. Pencil beams scan through a target
volume multiple times until the original fraction dose is accumulated. SFUD fields are
currently used at CPT PSI for 4D treatments. In the scope of this project, properties of
rescanned delivery have been tested for SFUD and for patched fields.
In the course of this chapter what has been done will be explained and the analytical
results obtained will be reported and discussed.
3.1 Patch field
In the delivery of proton therapy, it is sometimes necessary to split a field into two or
more parts, since the dimensions of the target volume exceed the deliverable size of the
gantry. In Gantry 2 the maximum area that can be treated is of 12 cm in T direction
and 20 cm in the U direction, but the size of patches can be reduced on a software level,
modifying the steering files setup. Conventionally the setup is set to 11 cm for the T
direction and 19 in the U direction, to keep 5 mm of margin between the target and the
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maximum lateral margin reachable by the beam.
The use of multiple-field patching can assist in maintaining target coverage and con-
formity [23] [44]. This technique has been created initially to combine two independent
fields to treat a single target volume, to avoid critical structures near the target [45].
Typical proton patched-field treatment split one field in two, where one treats a
portion of the target and the second field treats the remainder of the target; generally
the two portions correspond to the half of the total volume. The challenge of using this
technique is to achieve a homogeneous dose distribution also in the patching zone, since
the presence of hot and cold spots in the target may lead to suboptimal treatment. In
4D-plans this goal is made more difficult due to the presence of the movement of the
target and of the OARs.
The target dose uniformity may be improved in spot-scanning treatments by optimiz-
ing dose spot weights in the area where the dose distributions overlap or get in contact
[46]. Alternatively, spot sizes may be chosen such that the penumbrae from various
beam spots contributing to the patch region are selected to sum to a homogeneous dose
[47]. These techniques are possible due to the flexibility of spot-scanning deliveries and
require the ability to choose a wide range of spot intensities, sizes, and locations within
a target.
For this study, different configurations were investigated, in order to find the best
one. Two parameters were changed: number of volumetric rescanning (1,4 or 8 rescans)
and overlapping region between the patches (0, 1 or 2 cm overlapping), so that we had
9 different combinations for every plan. No greater overlap has been investigated, to
avoid the risk of obtaining more patches, while a greater number of rescans would lead
to a release time too high. 4DDC in case of rescans and/or patch overlap proceeds with
an optimization of dose spot weights, in order to split the total dose of the spot, until
a minimum is reached. Under this lower limit the number of rescans will be limited.
Currently, 4D-treatments that require patches are rejected or are treated with normal
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3D-plans.
Figure 3.1: Schematic representation of an overlapping patch field with desired homoge-
neous dose and possible hot and cold spot.
3.2 4D Dose Calculation
Treatment Planning Systems (TPS) that calculate treatment plans are complex software
systems, which makes comprehensive testing, commissioning and quality assurance dif-
ficult. In addition to this, the delivery of a PBS treatment plan requires at least two
transformations of the resultant 3D Bragg peak fluence map resulting from TPS opti-
mization [49]. In a first step, this needs to be converted into machine-readable files,
which in a second moment have to be correctly interpreted and delivered by the treat-
ment machine. Both transformations are potential sources of errors which can be hard
to detect, especially given the complexity of individual fields. Indeed, from the machine
point of view, the translation of the fluence map from TPS to treatment machine is not
always straightforward. Due to dynamic effects, as well as random “noise” during deliv-
ery (e.g. magnet hysteresis, current fluctuations), the actually delivered spot positions
can vary from the planned positions by the order of up to a millimeter. For instance, at
the PSI Gantry 2, the relative and absolute spatial accuracy of each pencil beam need
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to be substantially improved through the use of spot specific positional offsets obtained
from an initial delivery of each field in an approach called “teaching” [48].
4DDC requires motion vectors and plan files: the former are extracted by a 4DCT
or a 4DCT(MRI) while the latter are generated starting by plan information and are
created during the 4D workflow (shown in Figure 3.2). Plan files are of two kinds: TPS
field and plan data, and steering files.
TPS field and plan data
A typical PBS plan is made up of one or several fields, where each field consists of
several thousand pencil beams delivered at a given gantry and a table angle. During
the planning step, for each of these angles, Bragg peaks are placed on a rectilinear grid
inside the target (with a user-defined margin) and iteratively optimized to achieve a
homogeneous dose distribution in the target [23] [24]. If the fields are optimized one
by one, this results in an SFUD plan. If the individual fields are allowed to be non-
homogeneous, better OAR sparing can be achieved as part of an IMPT plan. As a result
of this optimization, each such field in the treatment planning system is represented as
a set of binary files with a standard header and a data block containing, for each pencil
beam, its energy, lateral position and the optimized number of protons.
Steering files
For the machine to deliver a planned field, the spot by spot information need to be
translated into machine parameters which are fed to the treatment machine by steering
(machine control) files. This step is handled by a separate program, the so-called Steering
Files Generator (SFGen). Relevant data in these files for the 4DDC are the beam line
settings required to provide the desired energy, the currents in the sweeper magnets for
the required lateral deflection and the position of the patient couch (expecially in case
of large targets that require field patching), as well as the extraction of the telescopic
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nozzle (a feature of Gantry 2 [12]), which impacts on the beam profile in air.
The steering files are binary files that contain control sequences for beam line settings,
table motions, nozzle positions (extraction) and spot deliveries. In addition, Gantry 2
is equipped with an automatic, single thickness pre-absorber plate (water equivalent
thickness of 4.1 cm) which can be introduced to reduce proton energy sufficiently enough
to deliver Bragg peaks to the surface of the patient. The necessity of this plate for any
spot is also sequenced into the steering files. For each spot, the required currents for
both sweeper magnets as well as the required number of monitor units in the primary
beam monitor are defined. This “forward translation” from positions to magnet currents
is performed by SFGen using a 2D higher order polynomial fit. For the steering file
based dose calculation, the expected spot positions are then reconstructed from these
nominal currents of the sweeper magnets. However, as an analytical inversion of this fit
is difficult, this reconstruction is performed using an independent fit.
Finally, the monitor units (MU) for each pencil beam can be calculated directly form
the number of protons Np according to [49]
MU = Gel ·GIC ·
1
ρ
dE
dx
(E) · C(E) · e ·Np (3.1)
where 1
ρ
dE
dx
is the stopping power and e the elementary charge. Gel is the gain of mea-
surement electronics [ MU/nC], determined by characterization measurements. GIC is
the ion chamber gain [g/MeV/cm2 ], depending on the geometry of the detector and
obtained by Faraday cup measurements [50]. C(E) is an energy dependent factor that
was introduced to correct for energy dependent deviations observed in the Faraday cup
measurements of the ion chamber gain. These Faraday cup measurements have tradi-
tionally been the basis for absolute dosimetry at PSI, thus the monitor chambers are
calibrated in number of protons and dose to water. While this is a somewhat uncommon
approach, it allows to break the dose calculation to the single proton level.
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Calculation
The TPS for dose calculation developed at PSi is based on ray casting pencil beam model
[52], all information is taken from the files described above. First, a dose grid in the beam
coordinate system (s, t, u where s is parallel to the incident beam direction) is created
covering a volume of interest in the patient geometry. The spacing of the dose grid point
can be arbitrary and does not depend on the resolution of the underlying CT image.
The TPS then calculates successively the dose for each proton beam at all affected dose
grid.
The overall dose at one grid point position is given by the sum of doses from all
contributing pencil beams. To create a continuous dose distribution in the patient (CT)
coordinate system, the dose in between the dose grid points is then interpolated. Typ-
ically, the dose grid size for calculations in the s,t,u coordinate system is 5 x 5 x 5
mm.
To extend this to a 4D dose calculation, the pencil beam model has been adapted
to cope with target motion by adding time-dependent displacements for motion in the
t and u direction, respectively [51]. The starting point for the 4D dose calculations is
a static 3D treatment plan of TPS represented by a set of proton pencil beams (the
spot list) describing the position and the characteristics of each applied pencil beam. In
addition, for the 4D calculation individual time stamp (TS) is calculated for each pencil
beam. The TS depends on the number of protons delivered at each position and a set
of hardware parameters. The TS changes, for example, depending on the scanning path
and velocity (required dead times to adjust the beam position) and, if applied, the kind
of rescanning (2D/3D, scaled/iso-layered, number of rescans). This combination of a
pencil beam specific spot list and a set of timestamps completely describe the temporal
characteristics of treatment field delivery.
As for the motion of the patient geometry, this can be taken into account by using pre-
calculated displacement-maps derived for each motion phase (MP). The dose calculation
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is then performed on a continuously moving geometry, employing a linear interpolation
for the motion between any two MP. Thus the displacements are continuously calculated
and take into account in the dose calculation for a given pencil beam TS.
Finally, in order to deal with time-varying changes in densities and therefore proton
ranges, the algorithm uses pre-calculated density-variation-maps once again for each MP.
Water equivalent ranges at TS in-between two MP are chosen form the density-variation-
map closest time.
3.3 Clinical cases
For this study, 3 different patients were analyzed, with motion extracted by their 4D
CT, like for normal treatment planning. For the patient 16254 a treatment plan was also
studied with an extrapolated motion by a 4DCT(MRI) [53]. We took the decision of
simulating a motion, extracted by a volunteer’s 4DMRI, for three motivations: analyze
the behavior of a plan with 4 patches with more motion, add an intermediate configura-
tion between 4 mm of motion and 20 mm, confirm some indications that emerged from
others results. The usage of motion extracted by a 4DMRI gives the benefit of a more
realistic simulation of the respiratory motion. 4DCT motion is extracted and supposed
periodical combining 8 phases of the respiration (more than 8 CTs risk to give a too high
dose to the patient), while with MRI it’s possible to scan the motion for some minutes.
The limited number of clinical cases analyzed is due to a lack of patients treated,
since oncologists, generally, prefer to treat mobile tumors with other techniques.
Later the clinical cases will be exposed, reporting: kind of tumor, the extension of
the motion, an overview on the number of fields and number of patches, if preabsorber
was needed, and the size of the tumor in beam’s eye view. A representation of the CTV,
PTV and the patch zone will be included for all cases.
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(a) (b)
(c)
Figure 3.3: Representation of the CTV (white) and PTV (yellow) for the patient 16254.
Patch zone is shown with a with line. a coronal view, b axial view, and c sagittal.
Patient 16254
• Non-Hodgkin lymphoma
• Small motion (∼ 2 mm)
• 2 fields, 1 with 2 patches, 1 with 4 patches
• Preabsorber insert
• Dimension: 22.8 cm in U direction, 12.4 cm in T direction
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(a) (b)
(c)
Figure 3.4: Representation of the CTV (white) and PTV (yellow) for the patient 17914.
Patch zone is shown with a with line. a coronal view, b axial view, and c sagittal.
Patient 17914
• Neuroblastoma III
• Moderate motion (∼ 4 mm)
• 3 fields, 1 not patched, 2 with 2 patches
• Preabsorber mixed
• Dimension: 11.6 cm in U direction, 12.8 cm in T direction
Patient 16254 MRI
• Non-Hodgkin lymphoma
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(a) (b)
(c)
Figure 3.5: Representation of the CTV (white) and PTV (yellow) for the patient 16254
MRI. Patch zone is shown with a with line. a coronal view, b axial view, and c sagittal.
• Moderate motion (∼ 10 mm)
• 2 fields, 1 with 2 patches, 1 with 4 patches
• Preabsorber insert
• Dimension: 22.8 cm in U direction, 12.4 cm in T direction
Patient 17522
• Retroperitoneal liposarcoma
• Large motion (∼ 20 mm)
61
(a) (b)
(c)
Figure 3.6: Representation of the CTV (white) and PTV (yellow) for the patient 17522.
Patch zone is shown with a with line. a is coronal view, b is axial view, and c is sagittal.
• 2 fields, 1 not patched and 1 with 2 patches
• Preabsorber out
• Dimension: 10 cm in U direction, 12.4 cm in T direction
3.4 Results
For all patients, we investigated 9 possible combinations of the 4D plan, 3 different
setups of volumetric rescanning (1, 4, and 8) and 3 different overlapping setups (0, 1,
and 2 cm), and 1 3D plan, assumed as the optimum plan achievable for the patient.
The 4D workflow had to be hacked and modified since it was not possible to change the
overlapping region.
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After careful study, we have understood how to modify the procedure to generate the
4DDC, with a stand-alone version of SFGen. In normal procedure all the following steps
were made in just one “click”, but the timing.xml files should be changed:
• generation of field info files;
• generation by psiPlanProvider of a .tps file;
• creation of a timing.xml file (file that contain all the information about the 4D
setup designed);
• insert the timing.xml file in psiPlanProvider to produce the files used by the op-
timizer to generate the dose calculation, the so-called plan files (IPS2, TMST,
BTOP2, SPLI2, these files contain all information about spot position, energy and
time of delivery).
We had to code a new stand-alone version of the TPS (wrote in Java) that does not
proceed to generate by itself a timing.xml file, but that takes it from a folder where it
was previosly stored. The timing.xml file has to be generated with stand-alone version
of SFGen, in order to change manually the configurations of the setup that are desired.
The procedure to create a 4D plan can take from 4 to 6 hours for each one.
All the results in the following tables and histograms were extracted with the software
GUI Plan View. Histograms are the so-called Dose Volume Histogram (DVH), that are
instruments that permit to visualize in a precise way the dose absorbed by a certain
quantity of the volume, it is one of the most useful instruments to evaluate a plan. In
tables are reported values of dose homogeneity measures as: D5-D95 and V95. These
provide as results: the difference between the percentage of volume that receives 5% of
the prescribed dose and the percentage of volume that receive 95% of the prescribed dose,
and the percentage of volume that receive at least 95% of the prescribed dose. For D5-D95
a lower number corresponds to better results (since it means that the dose distribution
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is steep and close to the optimum), while for V95 a higher number corresponds to better
results (since it means that the volume of interest is all covered with enough dose).
3.4.1 Patient 16254
CTV
8 rescan 98.6 98.6 98.6
4 rescan 98.4 98.1 98.3
1 rescan 98.5 98.3 98 97.5
3D 0 cm 1 cm 2 cm
Table 3.1: V95 [%] 16254 Plan CTV
8 rescan 8.3 8.7 8.4
4 rescan 9.2 9.6 8.9
1 rescan 8.4 9.7 10 9.9
3D 0 cm 1 cm 2 cm
Table 3.2: D5-D95 [%] 16254 Plan CTV
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Figure 3.7: DVH for 16254 CTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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PTV
8 rescan 92.3 92.2 91.8
4 rescan 91.7 91.7 91.3
1 rescan 92.3 91.5 91 90.4
3D 0 cm 1 cm 2 cm
Table 3.3: V95 [%] 16254 Plan PTV
8 rescan 12.8 13.2 12.8
4 rescan 13.4 13.6 13.5
1 rescan 12.4 14 14.1 14.4
3D 0 cm 1 cm 2 cm
Table 3.4: D5-D95 [%] 16254 PTV
Figure 3.8: DVH for 16254 PTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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3.4.2 Patient 17914
CTV
8 rescan 99.9 99.9 99.9
4 rescan 97.9 98.9 99.2
1 rescan 99.9 97.9 96.9 98
3D 0 cm 1 cm 2 cm
Table 3.5: V95 [%] 17914 CTV
8 rescan 3.1 3.7 3.5
4 rescan 7.2 5.8 5.4
1 rescan 1.8 7.9 9.5 9
3D 0 cm 1 cm 2 cm
Table 3.6: D5-D95 [%] 17914 Plan CTV
Figure 3.9: DVH for 17914 CTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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PTV
8 rescan 95.1 94.9 94.8
4 rescan 91.2 93.6 94.1
1 rescan 92.3 90.8 90.9 91.5
3D 0 cm 1 cm 2 cm
Table 3.7: V95 [%] 17914 Plan PTV
8 rescan 8.1 8.7 8.7
4 rescan 11.7 9.9 9.6
1 rescan 7 12.9 14.4 13.9
3D 0 cm 1 cm 2 cm
Table 3.8: D5-D95 [%] 17914 Plan PTV
Figure 3.10: DVH for 17914 CTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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3.4.3 Patient 16254 MRI
CTV
8 rescan 96.7 96.5 96.5
4 rescan 96.8 96.1 95.2
1 rescan 98.5 93 92 92.9
3D 0 cm 1 cm 2 cm
Table 3.9: V95 [%] 16254MRI Plan CTV
8 rescan 10.1 9.8 9.6
4 rescan 11.1 12.1 13.7
1 rescan 8.4 15.6 16.4 15.5
3D 0 cm 1 cm 2 cm
Table 3.10: D5-D95 [%] 16254MRI Plan CTV
Figure 3.11: DVH for 16254MRI CTV. In red is represented 3D plan, in blue the best
curve of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve
of 4D-8rescan.
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PTV
8 rescan 89.4 89.2 90.2
4 rescan 89.8 88.2 88.4
1 rescan 92.3 87.7 85.7 87
3D 0 cm 1 cm 2 cm
Table 3.11: V95 [%] 16254MRI Plan PTV
8 rescan 16.1 15.1 14.7
4 rescan 15.8 17.3 18.2
1 rescan 12.4 18.3 19.6 18.4
3D 0 cm 1 cm 2 cm
Table 3.12: D5-D95 [%] 16254 MRI Plan PTV
Figure 3.12: DVH for 16254MRI PTV. In red is represented 3D plan, in blue the best
curve of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve
of 4D-8rescan.
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3.4.4 Patient 17522
CTV
8 rescan 80.3 79.8 79.1
4 rescan 82.1 81.8 82.8
1 rescan 70.9 79.9 79.4 78.8
3D 0 cm 1 cm 2 cm
Table 3.13: V95 [%] 17522 Plan CTV
8 rescan 27.3 25.4 23.6
4 rescan 25.4 26.5 25.9
1 rescan 23 31.4 32.4 32.8
3D 0 cm 1 cm 2 cm
Table 3.14: D5-D95 [%] 17522 Plan CTV
Figure 3.13: DVH for 17522 CTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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PTV
8 rescan 68.7 67.2 66.6
4 rescan 69 69.1 69.2
1 rescan 60.1 67.4 67 66.4
3D 0 cm 1 cm 2 cm
Table 3.15: V95 [%] 17522 Plan PTV
8 rescan 33.9 32.1 29.6
4 rescan 32 33.4 32.5
1 rescan 23.4 41.1 40.5 40.5
3D 0 cm 1 cm 2 cm
Table 3.16: D5-D95 [%] 17522 Plan PTV
Figure 3.14: DVH for 17522 PTV. In red is represented 3D plan, in blue the best curve
of 4D-1rescan, in green the best curve of 4D-4rescan, and in grey the best curve of
4D-8rescan.
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3.5 Discussion of the results
Since the purpose of the study was to verify the possibility to deliver a 4D plan that
requires patches, the first verification made was in a visual way. No tools existed to dis-
play the location of the patch, so during the thesis a workflow to permit the visualization
of a single patch was elaborated. Starting by the steering files it has been generated a
“Phys file”, that is a human-readable kind of file containing a spot list with energies of
protons and the location of the spot with reference to the isocenter of the patch. Once
the list has been modified, in order to have only those spots pertinent to a given patch
the dose is calculated again with an external tool called IDC [49]. Some example of dose
for a single patch is shown in Figure 3.15. By a first coarse analysis, just visualizing the
dose in the patching zone, no evidence of dose heterogeneity emerged.
(a) (b)
Figure 3.15: In figure a it is possible to see the dose for just 1 patch of 4 for the patient
16254. In figure b it is possible to see the dose for just 1 patch of 2 for the patient 17522.
In both pictures the contour of the CTV is also shown.
More significant studies were performed using dose homogeneity measures as: D5-D95
and V95.
All the results are shown in the subsection above, that is named “Results”, and
analysis on CTV results showed that size of overlap does not appear to influence the
outcome in a systematic fashion, while an higher number of rescanning generally gives
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better results. We found that the results could be split in 3 groups depending on their
motion: small motion (under 2 mm), moderate motion (between 3 mm and 10 mm),
strong motion (over 10 mm).
Patients are sorted for size of the motion, that is ∼ 2 mm for patient 16254, ∼ 4 mm
for patient 17914, ∼ 10 mm for the patient 16254MRI, and ∼ 20 mm for the patient
17522 (this is also the maximum level of motion that is acceptable at PSI). We can see
by values in Table 3.1 and in Table 3.2, that for small motion no mitigation is needed,
as we reach acceptable coverage and heterogeneity level also with 1 rescan. We can
see from Table 3.5, Table 3.6, Table 3.9, and Table 3.10 that with moderate motion,
some mitigation start to be needed, since it is not reached an acceptable level of dose
homogeneity or the increase in benefits is evident.
Analysis on the patient 17522 was tricky, since the plan needed was not a simple
SFUD, but an IMPT, because the CTV was overlapping with an OAR (bowel) as shown
in Figure 3.16. IMPT plans for 4D case are still not tested and not implemented in the
clinical procedure. For those reasons all the results are not acceptable, but it is still
possible to extract some useful information. From Table 3.13 and Table 3.14 it emerges
that strong mitigation is needed and by a visual analysis of the shape of DVH (example
in Figure 3.13) it is clear that increasing the number of rescanning and the overlapping
region the algorithm of optimization tends to follow the shape obtained in 3D plan.
PTV analysis are less robust and not so significant, since the algorithm, that optimizes
the dose, works on the optimization only of the CTV zone, and because the PTV concept
is less meaningful in 4D treatments. However, some indications can be extracted, like
that an increase of overlap generally gives better results, especially with mitigation of
the motion involved.
In order to improve the general 4D workflow, we have designed a new version of
the MATLAB script to select the correct mid-ventilation phase. The new version was
created because patient 16254 was affected by local metastasis that, since they were
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Figure 3.16: Dose distribution in 17522, it is possible to see that the overlapping between
the CTV(white) and the bowel (yellow) corrupt the homogeneity of the dose. Blue
indicates zone where the level is ∼ 100%.
located in a different region of the thoracic chest, could move in different ways. The
version elaborated during this work permits to analyze the density of superficial spots of
the tumor so as to cluster all the local metastases and return the mid-ventilation phase
for each one. A more accurate analysis, and plan design can be done with the new script
as we can perfectly know if all the metastases have the same mid ventilation or not. The
cluster analysis works on information extracted from a DICOM file and the clustering
algorithm is the so-called DBSCAN (Density-Based Spatial Clustering of Application
with Noise), a nonsupervised algorithm of clustering. A nonsupervised cluster algorithm
was chosen since no previous information about the number or location of the clusters
are know a priori. The output of the program is a figure that shows the shape of the
tumor with a different color for every metastasis and pictures that show the movement
of the tumor and the midventilation phase.
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Chapter 4
Experimental results
Following the analyzes described above, experimental checks were carried out, so as to
examine the correct delivery of the beam. In the chapter the experimental setup will be
presented, as well as the techniques used for the correct beam delivery and the results
of the gamma analysis. A short discussion will follow to comment the results.
4.1 Experimental setup
All the acquisitions were done at Gantry 2 since, at the time of my thesis internship, it
was the only gantry in which it was possible to make 4D treatments, now also Gantry 3
it’s available. The plans were recalculated in water geometry and the specific depth was
simulated with plexiglass, that has a ”water equivalent thickness”, for protons, of 1.7
[54]. A 2D array detector (PTW Octavius 1500) was mounted on QUASAR Respiratory
Motion Platform, and the delivery was regulated by an in house gating system.
PTW Octavius 1500
The OCTAVIUS Detector 1500 is an ion chamber matrix in a plane used for radiation
therapy verification and quality control. An ionization chamber, basically, consists of
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a gas volume between two electrodes connected to a high voltage supply of typically
100V to 1000V. In this gas volume, ionizing radiation creates ion pairs. These, being
positive and negative charge carriers, are attracted by the electrodes thus creating a
current which can be measured by an electrometer. Gas (air) volumes vary for 0.005
cm3 to 50000 cm3, and the corresponding currents can be between 10−14 A and 10−7
A. Using non-polar fluids, liquid-filled ionization chambers can be realized. Utilizing ion
chambers avoids radiations defects, the major drawback of solid-state detectors
The plane-parallel ion chambers are 4.4 mm x 4.4 mm x 3 mm in size (0.06 cm3),
and the center-to-center spacing is 7.1 mm. In total 1405 ion chambers are located in a
chessboard matrix, providing a maximum field size of 27 cm x 27 cm. This device has
a range of use that goes from 0.5 Gy/min to 48 Gy/min, with a resolution of 0.1 mGy
and 0.1 Gy/min [55].
Figure 4.1: PTW OCTAVIUS 1500 [55]
Gating system
A gating system has been used as a trigger for the delivery, so that all irradiations start
when the platform was in a certain position. This technique was introduced to reduce
the delivery uncertainties derived by a random choice of the starting point. To check
the motion it has been used an optical tracking system, Polaris SPECTRA, produced
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by Northern Digital Inc. [57] .
Polaris SPECTRA is a position sensor that measures the location of either active
or passive infrared markers. Three-dimensional localization relies on stereo photogram-
metry theory to triangulate a marker point from multiple calibrated views of the scene
that are acquired with two sensors embedded in the device. The Position Sensor emits
infrared (IR) light from its illuminators, like the flash on a conventional camera. The
IR light floods the surrounding area and reflects the Position Sensor off passive sphere
markers (on passive tools) or triggers markers to activate and emit IR light (on active
wireless tools). A System Control Unit (SCU) activate the markers on the active tools,
causing them to emit IR light, the Position Sensor then measures the positions of the
markers and calculates the transformations (position and orientation) of the tools to
which the markers are attached. The Position Sensor transmits the transformation data,
along with status information, to the host computer for collection, display, or further
manipulation. When connected to the SCU, the Position Sensor can track three types
of tools: passive tools, active wireless tools, and active tools.
Figure 4.2: The optical tracking system, Polaris SPECTRA [56]
Motion Platform
The motion was simulated using two different kinds of curves to simulate moderate and
strong motion, the 2D array was mounted on QUASAR Respiratory Motion Platform.
The QUASAR Respiratory Motion Platform is designed to move an existing phantom
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or detector with programmable respiratory and sinusoidal motion profiles for patient-
specific QA. The platform, 35 x 35 cm, allows moving in the superior/inferior direction
with amplitudes up to 2 cm.
Figure 4.3: Representation of the full experimental setup used at Gantry 2.
Teaching
All fields were taught and boosted. To generate steering files from the TPS system,
sweeper magnet currents are calculated from the nominal spot positions by a 2D higher
order polynomial fit. However, as Gantry 2 was designed to allow for fast energy changes
for 3D scanning, dynamic and magnetic hysteresis effects are not fully addressed by these
static sweeper maps. To account for such effects, additional spot by spot offsets are
determined based on positions measured in the nozzle [49]. This process, referred to as
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steering file teaching, is performed as part of the plan verification. After the first delivery
of an unmodified steering file to a phantom, the logged position errors (of the order of
one millimeter) are used to calculate corrections, using a smoothing approach to avoid
over-correcting random effects. After such corrections, the steering files are designated
as being ‘taught’ [48].
4.2 Results
The results presented here were obtained with gamma analysis made with Verisoft soft-
ware. The gamma score presented in tables offers a composite analysis with a percent
dose diffence (DD) and a distance-to-agreement (DTA) collapsed into one parameter.
The gamma is defined as the square root of a linear quadratic addition of the two fac-
tors, while they are provided in relative magnitude to their acceptance criteria (CDTA
and CDD) as shown [59]
Γ =
√(
DTA
CDTA
)2
+
(
DD
CDD
)2
.
The delivery of a plan is acceptable if it satisfies the minimum value of 90%.
There are presented also tables with time of delivering every field test, with the
percentage indication of how much is the increase respectly to the deliver of a 3D/1
rescan plan.
4.2.1 Patient 17914
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Table 4.1: Gamma analysis of patient 17914 Field 1
8 rescan x 93.1 95.1 93
4 rescan x 92.1 93.1 94.1
1 rescan - - - -
3D 0 cm 1 cm 2 cm
Table 4.2: Time of delivering Field 1 of patient 17914
8 rescan x
8’52”
(521%)
8’49”
(519%)
11’
(1219%)
4 rescan x
5’05”
(299%)
5’04”
(298%)
5’03”
(297%)
1 rescan 1’42” - - -
3D 0 cm 1 cm 2 cm
Table 4.3: Gamma analysis of patient 17914 Field 2
8 rescan x 86.3 - 89.9
4 rescan x 88.4 - 87
1 rescan - - - -
3D 0 cm 1 cm 2 cm
Table 4.4: Time of delivering Field 2 of patient 17914
8 rescan x
10’
(1071%)
-
11’
(1219%)
4 rescan x
5’11”
(555%)
-
5’09”
(552%)
1 rescan 56” - - -
3D 0 cm 1 cm 2 cm
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(a) (b)
(c) (d)
Figure 4.4: 17914 2 cm overlap 4 rescan, 6.8 water equivalent. On the left there is a
representation of F1, while on the right there is a representation of F2.
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4.2.2 Patient 16254
Table 4.5: Gamma analysis of patient 16254 Field 2
8 rescan x 97.9 97.8 98.3
4 rescan x 99 98.6 97.4
1 rescan - 95.7 92.2 91.3
3D 0 cm 1 cm 2 cm
Table 4.6: Time of delivering Field 2 of patient 16254
8 rescan x
11’52”
(520%)
12’04”
(528%)
12’16”
(537%)
4 rescan x
7’12”
(315%)
6’59”
(306%)
7’05”
(310%)
1 rescan - 2’17” 2’44” 2’25”
3D 0 cm 1 cm 2 cm
Table 4.7: Gamma analysis of patient 16254 Field 2 with strong motion
8 rescan x 85.8 87.9 90.2
4 rescan x - - -
1 rescan - - - -
3D 0 cm 1 cm 2 cm
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(a) (b) (c)
Figure 4.5: Comparison of gamma score for 16254 F2 delivered with strong motion
simulation.
Table 4.8: Gamma analysis of patient 16254 Field 1
8 rescan x - - 90.2
4 rescan x - - -
1 rescan - 95.6 - 92.3
3D 0 cm 1 cm 2 cm
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4.3 Discussion of the results
Experimental verification was done to check the correct delivery of the beam since many
problems occurred in past years when spot energy was too low due to the overlapping
region of patches. Due to limited time available at the gantry, since for experimental
verification can be done only during night. We have been forced to take the decision to
simulate only two plans, 17914 and 16254.
In order to deliver properly a patch field, it was not possible to follow the normal
procedure; in fact the main problem was to leave the couch move while keeping the ex-
perimental mode on. We solved this problem generating new steering files with a starting
couch position fixed and set on the first experimental session. New patch isocenter po-
sitions were calculated and inserted for all fields of all plans.
Two-dimensional gamma analysis (with the criteria of 3%/3mm [58]) were performed
between the measurements and the retrospectively calculated dose distribution, of the
3D plan, to quantify the quality of agreement between the 4D delivery and static plan.
The plan of the patient 17914 had 2 fields really similar to each other, as it is possible
to see in figure 4.4, but they gave different results, as it is shown in Tables 4.1 and 4.3.
No good explanation was found to justify this different behavior. A similarity was found
in time to delivery both fields as it is possible to see in Tables 4.2 and 4.4.
The plan of the patient 16254 was a more interesting as case as it has a field that
needs 4 patches so region that can achieve a maximum of 32 rescans. For this motivation
Field 2 was delivered in all possible combinations and with strong motion simulation,
Field 1 was only tested in few combinations to verify the correct delivery. Very good
results were obtained for F2 in all setup combinations as it is possible to see in Table
4.5, especially with mitigation of motion involved. Strong motion still gave good results
and indications regarding a benefit induced by the increase of overlapping regions have
emerged, confirming the analytical results. Time to delivery F2 were comparable with
17914 one (Table 4.6. By Figure 4.5 it emerges that, even in the most critical situations,
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there is no degradation of the dose around the patching zone, also in the region of 4cm2
that receives 32 rescans.
Also with the benefit induced with 8 rescans and patching, it doesn’t seem practical
due to large irradiation times, it is suggested to use this combination only if really needed,
otherwise 4 rescans should be used.
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Conclusions
In this thesis, we investigated the feasibility to deliver 4D treatment plans when it is
required the use of patches. The verifications were done in analytical and experimental
way.
For the analytical part, it was first necessary to create a tool that allows the vi-
sualization of the patch area, to permit a first rough verification, visualizing the dose
calculation. There were no inhomogeneities of visible dose. A new procedure for 4DDC
was realized during this work to allow to have different setups, as in a normal procedure
it is possible to change only the number of rescans. By the results obtained it is possible
to say that for small respiratory motion (under 2 mm), no mitigation of the motion is
needed, for moderate motion (between 2 and 10 mm), some mitigation of the motion is
needed, but also that 4 rescans are enough. Size of the patch overlap does not appear to
influence the outcome in a systematic fashion, however, there were some cases, especially
for strong motion, where 2cm overlap showed better results.
Experimental delivery required particular attention to the generation of the steering
files since it was not possible to proceed with standard procedure, as the couch had
to move. Measured data doesn’t show any remarkable dose degradation within the
overlap area and good gamma scores were achieved. The only problem that emerged
was a strange behavior with F2 of patient 17914 that performed bad, while the really
similar F1 of the same patient achieved good results. It was not possible to understand
the motivations behind those differences. The only field delivered with strong motion
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simulation gave results that indicated the benefit of using larger overlap. Combination
of 8 rescans and patching doesn’t seem practical due to large irradiation times.
An outlook for this study will be certain to add more patient’s data when available
to give more robustness to the study. Another improvement that will be done in next
period is to produce 4DDC log files based, so that the experimental verification will be
3D and not only 2D, as it is with normal gamma analysis obtained by a revelator.
In order to improve the 4D workflow we have designed a new version of the MATLAB
script to select the correct mid-ventilation phase. Now it is possible to make more
sophisticated analysis, taking into account the presence of metastasis and that those can
move in a different way respect to each other.
After this work, it is possible to proceed with the introduction in the clinic procedure
the treatment of 4D patients that require patches.
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Acronyms
4DDC 4D Dose Calculation MFO Multi-Field Optimization
CBCT Cone Beam Computed Tomography MP Motion Phase
CGE Cobalt Grey Equivalent OAR Organ At Risk
CPT Center for Proton Therapy PBS Pencil Beam Scanning
CT Computed Tomography PET Positron Emission Tomography
CTV Clinical Target Volume PSI Paul Scherrer Institute
DD Dose Difference PTV Planning Target Volume
DTA Distance-To-Agreement RBE Relative Biological Effectivness
DVH Dose-Volume Histogram RPSP Relative Proton Stopping Power
GTV Gross Tumor Volume SFGen Steering Files Generator
IMPT Intensity Modulated Proton Therapy SFUD Single Field Uniform Dose
IR InfraRed SOBP Spread-Out Bragg Peak
ITV Internal Target Volume TPS Treatment Planning System
LET Linear Energy Transfer TS Time Stamp
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